Filing Analysis
Celularity Inc. disclosed a default notice from a lender due to delinquent SEC filings, alongside the departure of two senior executives and an amended $13.3 million asset sale agreement. The company failed to file its 2025 Form 10-K, triggering default provisions on a $1.97 million convertible note with an 18% interest rate.
Red Flags
- Notice of event of default on debt obligations.
- Delinquent SEC reporting (failure to file Form 10-K).
- Extremely high interest rate (18% per annum) on the Helena Note.
- Multiple high-level executive departures (CAO and a President) within one week.
- Mandatory default penalty of 115% of principal and interest.
- Multiple 8-K items (1.01, 2.03, 3.03, 5.02) indicating significant corporate distress.
Key Facts
- Entered Amendment No. 1 with NexGel, Inc. for an asset sale totaling $13.3 million, including $8.3 million in upfront cash.
- Received a notice of event of default on April 17, 2026, from Helena Global Investment Opportunities 1 Ltd. regarding a $1,970,502.58 convertible note.
- The default was triggered by the company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The Helena Note carries an 18% annual interest rate and includes a 'Mandatory Default Amount' penalty of 115% of the outstanding balance.
- Terminated CAO John R. Haines without cause on April 9, 2026; President of Degenerative Diseases Stephen A. Brigido resigned on April 15, 2026.
- Extended the outside date for the NexGel transaction to April 30, 2026.
Celularity Inc. entered into an agreement to sell and exclusively license its commercial-stage biomaterials portfolio and certain development programs to NexGel, Inc. for up to $35 million. The transaction includes a $15 million upfront cash payment and up to $20 million in milestone payments based on future net sales.
Red Flags
- Transaction completion is contingent on the buyer (NexGel) successfully obtaining financing, introducing significant closing risk.
- The divestiture of 'commercial-stage' assets may indicate a strategic pivot or a need for immediate liquidity.
Key Facts
- Agreement signed March 6, 2026, with NexGel, Inc. for the sale and exclusive licensing of the biomaterials 'Business'.
- Total potential consideration of $35.0 million, consisting of $15.0 million upfront and $20.0 million in sales-based milestones.
- The deal includes ancillary contract manufacturing and sublease agreements.
- Closing is contingent on NexGel receiving financing sufficient to cover the $15.0 million upfront payment.
Celularity Inc. announced that Joseph DosSantos, the SVP of Finance and Acting CFO, departed the company for personal reasons on February 27, 2026. John Sprague was appointed as the new Acting CFO effective the same day.
Red Flags
- Departure of the principal financial officer (Acting CFO) for 'personal reasons' can indicate underlying issues or lack of stability.
- The company continues to rely on 'Acting' leadership for the CFO role rather than a permanent appointment.
- Frequent turnover in the finance department for micro-cap companies often precedes reporting delays or restatements.
Key Facts
- Joseph DosSantos resigned as SVP, Finance and Acting CFO on February 27, 2026.
- The departure was attributed to 'personal reasons'.
- John Sprague was appointed as Acting CFO on February 27, 2026.
- The filing was submitted on March 5, 2026, following the February 27 event date.